WO2019019961A1 - Microflore destinée à la prévention et au traitement d'une réaction du tube digestif et/ou de la peau et son utilisation - Google Patents

Microflore destinée à la prévention et au traitement d'une réaction du tube digestif et/ou de la peau et son utilisation Download PDF

Info

Publication number
WO2019019961A1
WO2019019961A1 PCT/CN2018/096600 CN2018096600W WO2019019961A1 WO 2019019961 A1 WO2019019961 A1 WO 2019019961A1 CN 2018096600 W CN2018096600 W CN 2018096600W WO 2019019961 A1 WO2019019961 A1 WO 2019019961A1
Authority
WO
WIPO (PCT)
Prior art keywords
lactobacillus
bifidobacterium
package
cfu
bacteria
Prior art date
Application number
PCT/CN2018/096600
Other languages
English (en)
Chinese (zh)
Inventor
郑伟
张发明
承磊
龙雨
Original Assignee
海思科医药集团股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 海思科医药集团股份有限公司 filed Critical 海思科医药集团股份有限公司
Publication of WO2019019961A1 publication Critical patent/WO2019019961A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Abstract

L'invention concerne des bactéries intestinales composites pour prévenir et traiter une réaction du tube digestif et/ou de la peau et leur utilisation. Les bactéries composites comprennent au moins l'une des bactéries suivantes : lactobacillus plantarum, bifidobacterium longum, lactobacillus johnsonii, bifidobacterium infantis, lactobacillus salivarius, lactobacillus rhamnosus, lactobacillus acidophilus, lactobacillus helveticus, lactobacillus lactis, bifidobacterium lactis, bifidobacterium adolescentis, lactobacillus reuteri, bifidobacterium bifidum, lactobacillus gasseri, lactobacillus casei, lactobacillus paracasei, lactobacillus fermentum, bifidobacterium breve, lactobacillus brevis, bifidobacterium animalis, clostridium butyricum, bacillus licheniformis, lactobacillus delbrueckii and lactobacillus bulgaricus. Les bactéries composites sont utilisées pour contrôler et traiter une réaction indésirable du tube digestif et de la peau.
PCT/CN2018/096600 2017-07-26 2018-07-23 Microflore destinée à la prévention et au traitement d'une réaction du tube digestif et/ou de la peau et son utilisation WO2019019961A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710619061 2017-07-26
CN201710619061.X 2017-07-26

Publications (1)

Publication Number Publication Date
WO2019019961A1 true WO2019019961A1 (fr) 2019-01-31

Family

ID=65039404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/096600 WO2019019961A1 (fr) 2017-07-26 2018-07-23 Microflore destinée à la prévention et au traitement d'une réaction du tube digestif et/ou de la peau et son utilisation

Country Status (2)

Country Link
TW (1) TW201909908A (fr)
WO (1) WO2019019961A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900016805A1 (it) * 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
CN113413400A (zh) * 2021-06-02 2021-09-21 广州市锦盛生物科技有限公司 用于治疗特应性皮炎的微生物复合制剂
EP4032536A1 (fr) * 2021-01-26 2022-07-27 Probisearch, S.L.U. Composition probiotique pour nourrissons et ses utilisations
US11464814B2 (en) 2014-04-23 2022-10-11 Sofar Spa Topical composition for use in the treatment of inflammatory bowel disease
US11591416B2 (en) 2016-12-02 2023-02-28 Sofar S.P.A. Exopolysaccharides and uses thereof
CN115887505A (zh) * 2022-12-30 2023-04-04 北京农学院 动物双歧杆菌j-12干预口腔溃疡的作用效果
US11752179B2 (en) 2016-06-08 2023-09-12 Alfasigma S.P.A. Medical use of probiotics
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
US11839634B2 (en) 2013-09-06 2023-12-12 Alfasigma S.P.A. Use of a composition comprising microorganisms to increase the intestinal production of butyric acid, folic acid or niacin and/or decrease the intestinal production of succinic acid
US11896631B2 (en) 2016-12-16 2024-02-13 Alfasigma S.P.A. Probiotics for use in the treatment of diverticulosis and diverticular disease

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111705012B (zh) * 2020-05-22 2022-06-28 内蒙古蒙牛乳业（集团）股份有限公司 一种具有促进消化作用的副干酪乳杆菌lc-37及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012002322A1 (fr) * 2010-06-28 2012-01-05 株式会社ヤクルト本社 Agent d'amélioration des propriétés cutanées, destiné à être administré par voie orale
CN102740866A (zh) * 2009-05-11 2012-10-17 雀巢产品技术援助有限公司 短时间高温处理生成具有抗炎谱的微生物制品

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102740866A (zh) * 2009-05-11 2012-10-17 雀巢产品技术援助有限公司 短时间高温处理生成具有抗炎谱的微生物制品
WO2012002322A1 (fr) * 2010-06-28 2012-01-05 株式会社ヤクルト本社 Agent d'amélioration des propriétés cutanées, destiné à être administré par voie orale

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PARVEZ, S. ET AL.: "Probiotics and Their Fermented Food Products Are Beneficial for Health", JOURNAL OF APPLIED MICROBIOLOGY, vol. 100, no. 6, 30 June 2006 (2006-06-30), XP008104657, ISSN: 1364-5072, DOI: doi:10.1111/J.1365-2672.2006.02963.X *
ZHANG, SHANTING ET AL.: "Progress on the Studies and Application of Clostridium Butyricum", BIOTECHNOLOGY BULLETIN, 10 September 2013 (2013-09-10), ISSN: 1002-5464 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11839634B2 (en) 2013-09-06 2023-12-12 Alfasigma S.P.A. Use of a composition comprising microorganisms to increase the intestinal production of butyric acid, folic acid or niacin and/or decrease the intestinal production of succinic acid
US11464814B2 (en) 2014-04-23 2022-10-11 Sofar Spa Topical composition for use in the treatment of inflammatory bowel disease
US11752179B2 (en) 2016-06-08 2023-09-12 Alfasigma S.P.A. Medical use of probiotics
US11591416B2 (en) 2016-12-02 2023-02-28 Sofar S.P.A. Exopolysaccharides and uses thereof
US11896631B2 (en) 2016-12-16 2024-02-13 Alfasigma S.P.A. Probiotics for use in the treatment of diverticulosis and diverticular disease
CN114727640A (zh) * 2019-09-20 2022-07-08 索法尔公司 细菌菌株、其组合物以及其用于治疗胃肠紊乱的用途
IT201900016805A1 (it) * 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
WO2021053639A1 (fr) * 2019-09-20 2021-03-25 Sofar S.P.A. Souches bactériennes, leurs compositions et leur utilisation pour le traitement de troubles gastro-intestinaux
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
EP4032536A1 (fr) * 2021-01-26 2022-07-27 Probisearch, S.L.U. Composition probiotique pour nourrissons et ses utilisations
WO2022161928A1 (fr) * 2021-01-26 2022-08-04 Probisearch, S.L.U. Composition probiotique à base de lactobacillus salivarius et de bifidobacterium longum et ses utilisations
CN113413400A (zh) * 2021-06-02 2021-09-21 广州市锦盛生物科技有限公司 用于治疗特应性皮炎的微生物复合制剂
CN115887505A (zh) * 2022-12-30 2023-04-04 北京农学院 动物双歧杆菌j-12干预口腔溃疡的作用效果

Also Published As

Publication number Publication date
TW201909908A (zh) 2019-03-16

Similar Documents

Publication Publication Date Title
WO2019019961A1 (fr) Microflore destinée à la prévention et au traitement d'une réaction du tube digestif et/ou de la peau et son utilisation
Lenoir-Wijnkoop et al. Probiotic and prebiotic influence beyond the intestinal tract
US7638335B2 (en) Kit comprising antihuman TNF-α antibody and antihuman TNF-α antibody activity lowering inhibitor
US7628991B2 (en) Use of Lactobacillus farciminis for the prevention or treatment of digestive pathologies
Harmon et al. Perforated pseudomembranous colitis in the breast-fed infant
US20230072816A1 (en) Method To Improve The Health Of The Microbiome In A Human Gastrointestinal System And Multi-Chamber Probiotic Delivery Products Therefor
CN114425080A (zh) 脆弱拟杆菌与pd-1或pd-l1抗体联合用药治疗生殖泌尿系统癌症的应用
Zhang et al. Randomised clinical trial investigating the effects of combined administration of octreotide and methylglucamine diatrizoate in the older persons with adhesive small bowel obstruction
CN116617272A (zh) 一株罗伊氏乳杆菌在制备防治急性辐射肠损伤功能产品中的应用
WO2014076638A1 (fr) Composition antiparasitaire à large spectre à base de nitazoxanide, de probiotiques et prébiotiques
Daniluk et al. Probiotic-induced apoptosis and its potential relevance to mucosal inflammation of gastrointestinal tract
Ozen et al. Cefoperazone induced gastro-intestinal haemorrhage. A case report
KR20150123892A (ko) 카바지탁셀 및 전이성 전립선암 치료를 위한 그의 용도
CN110448569B (zh) 一种具有止泻功效的组合物及其制备方法和其应用
ES2763874B2 (es) Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades
JP7118594B2 (ja) 止瀉剤組成物
NL2025863B1 (en) Fecal matter for treatment of cachexia
Bisgard et al. Regional Ileitis (Crohn)
CN108079032A (zh) 八宝丹在制备抑制胃癌恶性发展的药物中的用途
Rani Comparative study of efficacy of cefuroxime and ceftriaxone in enteric fever
JP4868378B2 (ja) 炎症性腸疾患治療薬
RU2164800C1 (ru) Способ лечения альгоменореи у девочек-подростков
Hara CVIII Stricture of the Esophagus following Pregnancy: A Case Report
Tănăsescu et al. INTESTINAL OCCLUSION DUE TO INTUSSUSCEPTION IN THE ASCENDING COLON
Silbert Thrombo-angiitis obliterans and Addison's disease in the same patient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18837384

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 27/05/2020)

122 Ep: pct application non-entry in european phase

Ref document number: 18837384

Country of ref document: EP

Kind code of ref document: A1